Dianthus Therapeutics, Inc. /DE/

Developing selective antibody therapies for severe autoimmune diseases.

DNTH | NDAQ

Overview

Corporate Details

ISIN(s):: US2528281080 (+1 more)
LEI:
Country:: United States of America
Address:: 7 TIMES SQUARE, 10036 NEW YORK
Website:: https://dianthustx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies for severe autoimmune diseases. The company focuses on designing and engineering potentially best-in-class monoclonal antibodies with improved potency, high selectivity, and extended half-lives. Its lead candidate, claseprubart (DNTH103), is an antibody that selectively targets the active C1s complement protein. The pipeline also includes DNTH212, a bifunctional inhibitor targeting Type 1 IFN suppression and B cell modulation. Dianthus's therapeutic approach aims to enable less frequent and more convenient self-administered subcutaneous injections, with the goal of improving clinical outcomes and quality of life for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dianthus Therapeutics, Inc. /DE/ filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dianthus Therapeutics, Inc. /DE/

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Dianthus Therapeutics, Inc. /DE/ via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
China SXT Pharmaceuticals, Inc. Researches, produces, and sells advanced Traditional Chinese Medicine (TCM) herbal products.	United States of America	SXTC
ChoA Pharmaceutical Co., LTD. Global manufacturer of OTC medicines and health supplements distributed through pharmacies.	South Korea	034940
CHUGAI PHARMACEUTICAL CO., LTD. An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.	Japan	4519
Cinclus Pharma Holding AB Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.	Sweden	CINPHA
Cingulate Inc. Developing once-daily, precision timed-release drugs for ADHD and anxiety.	United States of America	CING
Circio Holding ASA Developing circular RNA vector tech and immunotherapies for gene and cell therapies.	Norway	CRNA
CITIUS ONCOLOGY, INC. Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.	United States of America	CTOR
Citius Pharmaceuticals, Inc. Late-stage biopharma developing critical care products for oncology, infections, and stem cells.	United States of America	CTXR
CJ Bioscience Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.	South Korea	311690
CKD Bio Corp. Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.	South Korea	063160